Key clinical point: Bone marrow mononuclear cells offer another promising cell therapy for early-stage treatment of ischemic stroke.
Major finding: Doses of bone marrow mononuclear cells up to 10 million cells/kg are well tolerated by patients within the first 72 hours post stroke.
Study details: A phase 1 study of 25 ischemic stroke patients.
Disclosures: The study was supported by grants from the National Institutes of Health. Dr. Savitz and many of his coauthors disclosed having numerous financial ties to the pharmaceutical and biotechnology industries.